Dextromethorphan Induced Dystonia: A Rare Case Report.

dextromethorphan dystonia extrapyramidal side effects neurological adverse effects

Journal

Hospital pharmacy
ISSN: 0018-5787
Titre abrégé: Hosp Pharm
Pays: United States
ID NLM: 0043175

Informations de publication

Date de publication:
Aug 2023
Historique:
pmc-release: 01 08 2024
medline: 26 6 2023
pubmed: 26 6 2023
entrez: 26 6 2023
Statut: ppublish

Résumé

Dextromethorphan is a distant derivative of morphine, used as an antitussive agent indicated in standard care for various infections and respiratory conditions ranging from the common cold (rhinoviruses) to severe acute respiratory illness (SARI). Being a derivative of morphine, a natural central nervous system (CNS) depressant, dextromethorphan produces little to no action on CNS when ingested in the prescription dosage. We present a case of a 64-year-old female patient, a known case of ischemic heart disease post angioplasty and stenting to the left anterior descending artery (LAD), with heart failure with reduced ejection fraction (HFrEF), diabetes, hypertension, chronic kidney disease, and hypothyroidism who developed extrapyramidal symptoms post dextromethorphan administration. The incidence of dextromethorphan-induced dystonia is unknown, and the literature review suggests 4 case reports indicating dextromethorphan-induced dystonia, and each of those reports is a case of either accidental overdose or overdose in substance abuse disorder. No cases of these CNS side effects are described among adults with a therapeutic dose of dextromethorphan. This case report serves to sensitize the clinician about this rare occurrence.

Identifiants

pubmed: 37360212
doi: 10.1177/00185787221150918
pii: 10.1177_00185787221150918
pmc: PMC10288457
doi:

Types de publication

Case Reports

Langues

eng

Pagination

353-356

Informations de copyright

© The Author(s) 2023.

Déclaration de conflit d'intérêts

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Ther Adv Neurol Disord. 2011 Jan;4(1):47-62
pubmed: 21339907
Am J Forensic Med Pathol. 1992 Dec;13(4):351-2
pubmed: 1288270
Pharmacol Ther. 2016 Aug;164:170-82
pubmed: 27139517
Mov Disord Clin Pract. 2015 Mar 28;2(3):299-300
pubmed: 30838232
Pharmacol Ther. 2016 Mar;159:1-22
pubmed: 26826604
J Toxicol Clin Toxicol. 1996;34(3):351-2
pubmed: 8667476
Med Hypotheses. 2012 Jun;78(6):693-702
pubmed: 22401777
Curr Opin Neurol. 2014 Aug;27(4):468-76
pubmed: 24978640
CNS Drugs. 2004;18(2):93-104
pubmed: 14728056
Eur J Paediatr Neurol. 2001;5(4):167-8
pubmed: 11587381
Pediatr Emerg Care. 1997 Jun;13(3):214-5
pubmed: 9220509
Drug Saf. 1992 May-Jun;7(3):190-9
pubmed: 1503667
Am J Health Syst Pharm. 2007 Nov 1;64(21):2241-3
pubmed: 17959575

Auteurs

Manjappa Mahadevappa (M)

JSS Medical College, Mysore, Karnataka, India.

Lakshay Kumar Attri (LK)

JSS College of Pharmacy, Mysore, Karnataka, India.

Sri Harsha Chalasani (SH)

JSS College of Pharmacy, Mysore, Karnataka, India.

Jehath Syed (J)

JSS College of Pharmacy, Mysore, Karnataka, India.

Classifications MeSH